Related Articles by Review for PMID: 22000811

Year	Number of Results
2008	2
2009	3
2011	2
2012	4
2013	2
2014	1
2018	2
2019	2
2020	5
2021	3
2022	1
2023	1
2024	1

1

A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.

Hainsworth JD, Schnabel CA, Erlander MG, Haines DW 3rd, Greco FA. Hainsworth JD, et al. Clin Colorectal Cancer. 2012 Jun;11(2):112-8. doi: 10.1016/j.clcc.2011.08.001. Epub 2011 Oct 14. Clin Colorectal Cancer. 2012. PMID: 22000811

2

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.

Pentheroudakis G, Greco FA, Pavlidis N. Pentheroudakis G, et al. Cancer Treat Rev. 2009 May;35(3):221-7. doi: 10.1016/j.ctrv.2008.10.003. Epub 2008 Nov 28. Cancer Treat Rev. 2009. PMID: 19046817 Review.

3

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Hainsworth JD, Greco FA. Hainsworth JD, et al. Virchows Arch. 2014 Apr;464(4):393-402. doi: 10.1007/s00428-014-1545-2. Epub 2014 Feb 1. Virchows Arch. 2014. PMID: 24487792 Review.

4

Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.

Overby A, Duval L, Ladekarl M, Laursen BE, Donskov F. Overby A, et al. Clin Genitourin Cancer. 2019 Feb;17(1):e32-e37. doi: 10.1016/j.clgc.2018.08.005. Epub 2018 Aug 28. Clin Genitourin Cancer. 2019. PMID: 30268423 Free article. Review.

5

Overview of various techniques/platforms with critical evaluation of each.

Agwa E, Ma PC. Agwa E, et al. Curr Treat Options Oncol. 2013 Dec;14(4):623-33. doi: 10.1007/s11864-013-0259-z. Curr Treat Options Oncol. 2013. PMID: 24243164 Review.

6

Cancer of Unknown Primary in the Molecular Era.

Kato S, Alsafar A, Walavalkar V, Hainsworth J, Kurzrock R. Kato S, et al. Trends Cancer. 2021 May;7(5):465-477. doi: 10.1016/j.trecan.2020.11.002. Epub 2021 Jan 28. Trends Cancer. 2021. PMID: 33516660 Free PMC article. Review.

7

New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?

Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N. Rassy E, et al. Crit Rev Oncol Hematol. 2020 Mar;147:102882. doi: 10.1016/j.critrevonc.2020.102882. Epub 2020 Jan 23. Crit Rev Oncol Hematol. 2020. PMID: 32106012 Review.

8

The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary^✰: Molecular profiling of metastatic cancer of unknown primary.

Dermawan JK, Rubin BP. Dermawan JK, et al. Semin Diagn Pathol. 2021 Nov;38(6):193-198. doi: 10.1053/j.semdp.2020.12.001. Epub 2020 Dec 4. Semin Diagn Pathol. 2021. PMID: 33309276 Review.

9

Progress in refining the clinical management of cancer of unknown primary in the molecular era.

Rassy E, Pavlidis N. Rassy E, et al. Nat Rev Clin Oncol. 2020 Sep;17(9):541-554. doi: 10.1038/s41571-020-0359-1. Epub 2020 Apr 29. Nat Rev Clin Oncol. 2020. PMID: 32350398 Review.

10

Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.

Greco FA. Greco FA. Curr Treat Options Oncol. 2013 Dec;14(4):634-42. doi: 10.1007/s11864-013-0257-1. Curr Treat Options Oncol. 2013. PMID: 23990214 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

22 results

Results by year